AI-Discovered Drugs Move Toward Clinical-Stage Financing

Enveda reportedly raised $311 million in a Series E at a $2 billion valuation, with named candidates entering human trials and reported Phase 1 results for ENV-308. The financing tests whether AI drug discovery can produce investable clinical assets, but approval, efficacy, safety, and later-stage validation remain open questions.